On July 7, 2022, Generon (Shanghai) Corporation Ltd. closed the transaction. Post the transaction, Sino Biopharmaceutical Limited and Yifan Pharmaceutical (Hong Kong) Co., Ltd. now hold 2.44% and 66.92% stakes in the company respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.84 HKD | -0.35% | +1.43% | -18.16% |
01:00am | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
05/06 | Sino Biopharmaceutical Presents Findings of Anti-Tumor Drug at American Cancer Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.16% | 6.69B | |
+43.19% | 749B | |
+39.42% | 605B | |
-6.74% | 351B | |
+18.91% | 328B | |
+7.83% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.38% | 167B | |
+6.89% | 165B |
- Stock Market
- Equities
- 1177 Stock
- News Sino Biopharmaceutical Limited
- Generon Corporation Ltd. announced that it has received $70.000203 million in funding from Sino Biopharmaceutical Limited, Yifan Pharmaceutical (Hong Kong) Co., Ltd.